

SYNTHESIS OF NEW PEPTIDYL DERIVATIVES FROM 4-THIAZOLIDONE

Ana Cristina Lima Leite*, Luciene Maria F. Santos, Janaina Versiani dos Anjos,
Maria Patricia Albuquerque de Farias, Ivone Antonia de Souza & Dalci José Brondani

Laboratório de Planejamento, Avaliação e Síntese de Fármacos - LABSINFA - Departamento de Ciências Farmacêuticas, Rua Prof. Artur Sa s/n – Cidade Universitária – Universidade Federal de Pernambuco, Recife-PE- Brasil
CEP: 50740-520 - aclb@ufpe.br

Abstract: In this work we report the synthesis of new heterocyclic compounds presenting a 4-thiazolidone nucleus and a peptidyl moiety. The synthesis has been achieved employing a strategy of peptide synthesis. Compounds **6a-e** were obtained in good overall yields and have been characterised by IR and the ¹H-NMR spectroscopy.

Introduction

The presence of the thiazole ring in compounds with a wide range of biological activities has contributed over the years to enlarge the interest for the closely related thiazolidones. Thiazole and thiazolidone nucleus are interesting because they present several biological properties like antimicrobial^{1,2}, anti-parasitic^{3,4}, antiinflammatory⁵, anticonvulsant⁶, cardiotonic⁷ and analgesic and antitermic⁸ activities, among others.

In addition to these findings it was found in Nature a group of cyclic peptides containing thiazolic heterocyclic rings, that are linked to amino acids blocks. Some of these cyclepeptides demonstrated antitumor and antimicrobial activities⁹⁻¹².

For some time, the interest for the design of prodrug containing an amino acid moiety or a peptidyl residue has increased. In fact, several research groups have been used amino acids looking for biologic active and low toxic molecules. As a matter of fact, the literature tells us that bioactive compounds have their activity improved when linked to amino acids¹³⁻¹⁹. These modifications have been based on the process of prodrug design as a way of molecular modification.

These facts concerned us to the synthesis of a new series of peptidyl compounds, embracing a 4-thiazolidone heterocyclic and a amino acid moiety. This paper reports the strategy of synthesising compounds **6a-e** applying the coupling reagents used in the peptide synthesis and the verification of their structures through spectroscopic means²⁰.

Results and discussion

In our strategy, we idealised initially to realise a protection of the amino group of thiosemicarbazide which is important to minimise the nucleophilic effect of primary amine of thiosemicarbazide that can difficult the ring formation. After that, a cyclisation reaction is easily realised in mild conditions. After removal of the protection group of heterocyclic ring, a condensation reaction with the several amino acids is proceed (Scheme I).

In order to protect the amine function of thiosemicarbazide we used the Boc (t-butoxycarbonyl) group, using the symmetrical anhydride (Boc)₂O (di-tert-butoxycarbonyl)²¹⁻²². The reaction passes on basic mean (NaOH), using dioxane as solvent. The intermediary compound **3** was obtained with 55% yield. On the second step, the cyclisation is realised through the reaction of the Boc-thiosemicarbazide and monochloroacetic acid in the presence of sodium acetate, utilising ethanol as solvent under reflux to obtain **4** with 78% yield. For the remotion of the Boc group of 4-

thiazolidone, a classical cleavage conditions using TFA/CH₂Cl₂ (1:1) ²¹⁻²² gives the deprotected 4-thiazolidone **5** (98% yield).

The last stage involves the condensation of the α -amino acids to the amine moiety of the 4-thiazolidone using DCC (dicyclohexylcarbodiimide) and N-hydroxysuccinimide to as a carbonyl activating agents²¹⁻². We had chosen using Boc (t-butoxycarbonyl) for N-terminal protecting group for this series.


Following this strategy initially five new molecules, compounds **6a-e** were obtained. This method gave incomes in the average of 15% to 98% for all the amino acids used.

The structures of **6a-e** were confirmed by spectral (IR and ¹H-NMR) data. IR spectra

The IR spectra were obtained on FTIR spectrophotometer Bruker, model IFS66 using KBr pellets. Peptidyl derivatives exhibited NH and C=O bands in the 3329-3323 and 1745-1627 cm^{-1} regions attributed to common CONH-N. The characteristic common to lactams C=O stretchings were observed in the 1730-1710 cm^{-1} region.

¹H-NMR spectra were measured with a Varian UNITY plus 300 MHz spectrophotometer using DMSO_{d6} as solvent and tetramethylsilane as an internal standard. Compounds **6a-e** displayed a single NH resonance (δ 7.9-8.0ppm), and the diagnostic S-CH₂ (δ3.48-3.27ppm). Concerning amino acid moiety, all compounds presented characteristic signals for NH and the proton linked to the chiral carbon. For the NH function, a characteristic doublet due to coupling with proton of chiral carbon (*J*=7.0 Hz) appeared δ 6.71-7.5ppm. Different chemical shifts for the groups next to the chiral center are observed, principally when bulky substituents are presented. Compound **6e** (a phenylalanine derivative) showed a multiplet (δ7.26-7.44ppm) indicating a typical aromatic hydrogen pattern. Some analytical data are shown in Table I

Scheme 1



a= dioxane / NaOH: b= ClCH_2COOH / H_3CCOONa :

$$\epsilon = \text{CF}_3\text{COOH} / \text{CH}_2\text{Cl}_2 \text{ (1:1)}; d = \text{BOC-NH-CH(R)-COOH} / \text{DCO/OHSu}$$

Table I- Analytical data 4-Thiazolidone derivatives

Compound	M. p. [°C] ^a	$[\alpha]_D^{20c}$	R_f^b	Molecular Formula	Yield (%)
6a	113-5	+19.8	0,74	C ₁₁ H ₁₈ N ₄ O ₄	96.7
6b	167-9	+15.4	0.78	C ₁₃ H ₂₂ N ₄ O ₄	96.5
6c	93-5	+14.0	0.81	C ₁₄ H ₂₃ N ₄ O ₄	15.0
6d	158-160	+19.8	0.80	C ₁₄ H ₂₄ N ₄ O ₄	95.2
6e	160-2	+16.5	0.76	C ₁₇ H ₂₂ N ₄ O ₄	98.10

^a Column chromatography solvent: Ethyl acetate/hexane (5/5); ^b Solvent system: Ethyl acetate/hexane (7:3); ^c Solvent DMSO, 4mg/mL.

Conclusion

Finally, the peptidyl derivatives from 4-thiazolidones were synthesised. The strategy using Boc-protection of thiosemicarbazide are promising and can be using for the synthesis of others series of thiazolidones derivatives. The biologic activity of these compounds is being determined. Some compounds are being submitted to antimicrobial tests, against microorganisms like gram positive and negative, alcohol acid resistant bacteria (Ziche-Nielsen), as well as filamentous fungi and leaven. In order to evaluate the anti-tumour activity, are being realised essays against sarcoma 180. These results will be reported in up coming.

Acknowledgements

We gratefully acknowledge the financial support of CNPq - "Conselho Nacional de Desenvolvimento Científico e Tecnológico " and the Departamento de Química Fundamental, Universidade Federal de Pernambuco (UFPE), for the recording the H-NMR and IR spectra of all compounds.

References

- 1- S. M. El-Khawass; M. A. Chaaban; *Il Farmaco*, 44(4) 415-421 (1989).
- 2- M. M. Dutta; B. N. Goswami; J. C. S. Katak; *J. Indian Chem. Soc.* 67, 332 (1990).
- 3- R. Cajouille; P. Loiseau; M. Payard, P. Gayral; *Ann. Pharmaceutiques Françaises*, 47(2): 68-72 (1889).
- 4- A. J. Alves; A. C. L. Leite; D. P. Santana; M. T. Beltrão; M. R. Coelho; P. Gayral; *Il Farmaco*, 48(8), 1167-1171 (1993).
- 5- I. P. Singh; A. Saxena; K. Shanker; *Eur. J. Chim.* 20(3): 283-6 (1985).
- 6- E. Medime; G. Çapan; *Il Farmaco*, 49(6), 449-451 (1994).
- 7- A. Andreani; M. Rambaldi; D. Bonazzi; G. Lelli; *Eur. J. Med. Chem.* 3(19): 219-222 (1984).
- 8- F. Bordin; P. L. Catellani et alli, *Il Farmaco*, 44(9): 795-807 (1989).
- 9- P. Wipf; *Chem. Ver.* 95, 2115-21-34 (1995)
- 10- G. Pattenden; *J. Heterocyclic Chem.*; 29, 607-18 (1992)
- 11- D. C. Boden; G. Pattenden; T. Ye; *Synlett*, 417-419 (1995).
- 12- K. Koeber-Plè; G. Massiot; *J. Heterocyclic Chem.* 32, 1309-1313 (1995).
- 13- A. Trouet, A. Passioukov, K. Derpoorten, A.M. Fernandez; J. Abarca-Quinones, R. Baurain, T. J. Lobl, C. Oliyai, D. Shochat, V. Dubois, *Cancer Research*, 61(7): 2843-2846 (2001).

- 14- P. K. Chakravarty,; P. L. Carl, M. J. Weber, J.A. Katzenellenbogen, J. Med. Chem., 26: 633-638 (1983).
- 15- P. K. Chakravarty, P. L. Carl, M. J. Weber, J. A. Katzenellenbogen, J. Med. Chem., 26: 633-638 (1983).
- 16- S. K. Aggarwal, S. R. S.Gogu, R. S. Rangan and K. Agrawal, J. Med. Chem., 33 p. 1505-10 (1990).
- 17- A. Philip, J. Kepler, B. Johnson and F. Carrol, J. Chem. Soc., 31, p. 870-4 (1988).
- 18- W. Arap, R. Pasqualini, E. Ruoslahti, Science, 279: 377-380 (1998).
- 19- Haines, D. Fuller, R. Ahmad, S. Vistica, D. and Marquez, V. J. Chem. Soc, 30, p. 542-7 (1987).
- 20- Abstracted in part, from M. Sc. Thesis L. M. F. Santos (Universidade Federal de Pernambuco), PE, BR, 2000.
- 21- M. Bodanszky– Peptide Chemistry – *A Practical Textbook*. New York: Springer-Verlag, 1988. 200p.
- 22- J. Jones, - The Chemical Synthesis of Peptides. New York: Oxford University Press, 1994. 229p.
- 23- Bodanszky, M. – Principles of Peptide Synthesis. New York: Springer-Verlag, 1984. 307p.

Received on August 20, 2002.